Ketan Mehta
Ketan Mehta is the chief executive of Tris Pharma, a company involved in developing new pain management therapies. He has overseen the development of cebranopadol, a novel painkiller that activates specific opioid receptors with a lower risk of addiction compared to traditional opioids.
Global Media Ratings
Countries Mentioned
| Country | Mentions | Sentiment | Dominance | + Persistence | x Population | = Reach | x GDP (millions) | = Power |
|---|---|---|---|---|---|---|---|---|
| Australia | 1 | 6.00 | 0.05% | +0% | 25,499,884 | 13,316 | $1,380,000 | 721$ |
| Totals | 1 | 25,499,884 | 13,316 | $1,380,000 | 721$ |
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
Australia:
Ketan Mehta was one of the bankers advising Cox.
6
United Kingdom:
Ketan Mehta is the chief executive of Tris Pharma.
7